Syniad’s Gemina Labs Announces Non-Brokered Private Placement

Vancouver, British Columbia – November 13, 2024: Syniad Innovations Inc. (“Syniad”) is pleased to share that Gemina Laboratories Ltd. (CSE: GLAB) (OTCQB: GLABF) (FRA:8I7) (the “Company” or “Gemina”), has announced a non-brokered private placement offering (the “Offering”) of up to 9,333,333 common shares in the capital of the Company (each, a “Share”) at a price of $0.75 per Share. The Offering is expected to raise gross proceeds of up to $7,000,000.

The net proceeds of the Offering will be used to accelerate the Company’s platform development, production expansion, business development and commercialization activities, and general working capital and corporate purposes. The securities issued under the Offering will be subject to a statutory hold period in Canada expiring four months and one day from the date of issuance.

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and binding technologies company initially focused on the diagnostics industry. Our technologies include transformative, patented, proprietary chemistries that power next generation testing platforms for a wide range of pathogens and other analytes that affect human health and wellness, driving testing platforms that are fast, affordable and accurate, and easily self-administered. More information about Gemina’s technology can be found here https://www.youtube.com/@GeminaLaboratories. Additional information on the Company can be found at www.geminalabs.com.